Cerus Corporation 2019 Form 10-K Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in transfusable platelets and plasma. Platelet and plasma systems were approved and commercialized in the U.S. and selected international markets; the red blood cell system remained in development. The filing covers the fiscal year ended December 31, 2019, with quarterly information provided for the three months ended December 31, 2019.
Cerus operated as one blood-safety segment and had 254 employees at year-end. Product revenue was generated primarily in Europe, the Middle East and Africa, and North America. Etablissement Français du Sang represented 27% of 2019 product revenue, while the American Red Cross represented 14%.
Financial performance and key metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Product revenue | $74.6 million | $60.9 million | +23% |
| Government contract revenue | $19.1 million | $15.1 million | +26% |
| Total revenue | $93.8 million | $76.1 million | +23% |
| Gross profit on product revenue | $41.2 million | $29.3 million | +41% |
| Product gross margin | 55% | 48% | +7 percentage points |
| Research and development expense | $60.4 million | $42.6 million | +42% |
| SG&A expense | $66.2 million | $56.8 million | +16% |
| Loss from operations | $(66.2) million | $(55.0) million | Loss increased |
| Net loss | $(71.2) million | $(57.6) million | Loss increased |
| Basic and diluted loss per share | $(0.51) | $(0.44) | Loss increased |
Approximate total-revenue operating margin was negative 70.6%, and net margin was negative 76.0%. These margins are calculated from reported revenue and losses and reflect continued significant investment in commercialization, clinical development and regulatory activities.
- Net cash used in operating activities was $65.8 million, compared with $31.2 million in 2018.
- Net cash provided by investing activities was $28.2 million, primarily reflecting investment maturities and sales.
- Net cash provided by financing activities was $43.5 million, including $26.9 million of equity proceeds and $44.4 million of debt financing proceeds, partly offset by debt repayments.
- Cash, cash equivalents and restricted cash totaled $37.4 million at December 31, 2019, including $35.0 million of cash and cash equivalents. Short-term investments totaled $50.7 million.
- Working capital was $77.8 million, down from $94.2 million.
- Debt carrying value was approximately $44.4 million, including $39.4 million of term debt and $5.0 million drawn under a revolving facility. Borrowings were secured by substantially all assets, subject to exclusions.
- Total contractual obligations were $103.6 million, including $56.2 million of debt obligations, $31.0 million of operating lease payments, $15.7 million of minimum purchase commitments and $0.7 million of other commitments.
Material changes versus the prior comparable period
- Product revenue increased $13.7 million, driven principally by increased U.S. platelet-system adoption and higher Middle East disposable-kit sales. France product mix and unfavorable euro translation partially offset growth.
- North American product revenue increased to $20.9 million from $12.7 million, while Europe, Middle East and Africa revenue increased to $52.5 million from $47.0 million.
- Product gross margin improved to 55% from 48%, primarily because of lower contract-manufacturer pricing, product mix improvement in France and stronger platelet demand.
- R&D expense increased $17.8 million, reflecting product enhancements, expanded-label initiatives, BARDA-related activities and development of extended-storage cryoprecipitate.
- Operating cash burn more than doubled, partly because of higher operating expenditures, inventory and payment timing, and a one-time $6.1 million payment to Fresenius.
- The company replaced its Oxford term loan with a MidCap term loan and revolving facility in March 2019. It recorded a $2.1 million loss on extinguishment of the Oxford debt.
- Cerus paid the remaining €5.5 million owed under its Fresenius manufacturing and development payment obligation in August 2019.
- The company adopted lease accounting under ASC 842 in 2019 and recorded operating lease right-of-use assets and liabilities.
Guidance, outlook, commentary and risks
- Management expected product revenue to increase over time with broader U.S. adoption and expansion in additional geographies, but stated that historical results may not be indicative of future performance.
- Management expected continued substantial losses and stated that profitability depends on widespread market adoption, additional regulatory approvals and effective execution of commercialization and development programs.
- The September 2019 FDA platelet-safety guidance requires blood collection facilities to comply with specified bacterial-risk-control options, including INTERCEPT, by March 31, 2021. Cerus warned that customer delays, manufacturing constraints or insufficient implementation resources could cause blood centers to select alternative options.
- The red blood cell system had completed European Phase 3 trials, but a supplier bankruptcy left Cerus without a qualified manufacturer for a key reagent beyond insufficient existing inventory. Cerus expected to refile under the European Medical Device Regulation and did not expect approval before 2022, if ever.
- U.S. red blood cell development continued through the RedeS and ReCePI Phase 3 studies. Additional chronic-anemia development and in-vitro work may be required before FDA consideration.
- Two non-hemolytic S-303 antibody events had been detected in the RedeS study. The filing states that the events were not considered clinically significant and had not raised safety concerns with the Data and Safety Monitoring Board; hemolytic antibody reactions could trigger a clinical hold.
- BARDA had committed approximately $103.2 million under the base period and exercised options, with potential total funding of up to $201.2 million. Additional funding depended on future options, milestones and government discretion; BARDA could terminate for convenience.
- Key operating risks include reliance on sole or limited-source suppliers, particularly Fresenius; manufacturing-component obsolescence; regulatory reapproval under the European MDR; concentrated customers and distributors; reimbursement and market-adoption uncertainty; foreign-exchange exposure; clinical-trial failure; and continuing need for external capital.
- In January 2020, Cerus sold 16.9 million shares at $3.75 per share for $63.3 million of gross proceeds before offering expenses.
Most important facts for investors to verify
- Reconcile the company’s cash runway against the $65.8 million 2019 operating cash burn, planned R&D spending and debt repayments.
- Review the terms, covenants, collateral and tranche conditions of the MidCap term and revolving loan agreements.
- Confirm the status and remaining funding availability of the BARDA agreement, including milestone requirements, audits and termination rights.
- Track U.S. adoption of INTERCEPT, customer implementation progress and compliance with the March 31, 2021 platelet-safety deadline.
- Verify progress toward qualifying a replacement red blood cell reagent supplier and the timing and requirements of MDR refiling.
- Assess customer concentration, especially the economic impact of EFS and American Red Cross purchasing levels.
- Evaluate inventory commitments, component obsolescence and dependence on Fresenius and other sole-source suppliers.
- Consider dilution from the January 2020 equity offering, the remaining at-the-market authorization and approximately 20.8 million weighted-average anti-dilutive potential shares.